Web Stats Provided By Google Analytics

Tuesday, September 20, 2016

Teva And Regeneron Announce Global Collaboration To Develop And...

Teva And Regeneron Announce Global Collaboration To Develop And Commercialize Fasinumab, An Investigational NGF Antibody For Chronic Pain JERUSALEM & TARRYTOWN, N.Y.-- --Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced today a global1 agreement to develop and commercialize fasinumab, Regeneron's investigational NGF antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global1 commercial value, as well as ongoing research and development costs of approximately $1 billion.
http://ift.tt/2cZPuWA

No comments:

Post a Comment

Popular Tarrytown Roundup Posts